TotalMarketCap

Denali Therapeutics

DNLINasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$3.165 B

$19.75 -5.80%

Close of 6 Nov 2026

As of 6 Nov 2026, Denali Therapeutics (DNLI) has a market capitalization of $3.16B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$0.00

#3616 by revenue

Earnings

-$512.5M

Loss-making

Shares outstanding

160,290,546

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #26Iovance BiotherapeuticsIOVA$3.49B
  2. #27Tarsus PharmaceuticalsTARS$3.33B
  3. #28Denali TherapeuticsDNLI$3.16B
  4. #29Adma BiologicsADMA$2.94B
  5. #30Beam TherapeuticsBEAM$2.68B

What if Denali Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$176,160.57

Per share 8,922× higher

Bitcoin $1.53T

$9,531.74

Per share 483× higher

Apple $5.02T

$31,291.82

Per share 1,585× higher

Or at a round number

$5.00B$10.0B$20.0B$50.0B

Where these numbers come from

Share counts and financials for Denali Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.